Therapy efficacy

The clinical outcome or success of treatment can, most of the time, only be determined long after initiation of therapy. Although clinical outcome is the most important endpoint parameter, the late identification of patients that do not benefit from therapy forms a clinical undesirable situation in that these patients are subject to the burden of ineffective therapy while simultaneously being withheld from alternative treatment options that might be beneficial. In addition, early identification of therapy responders and non-responders increases therapy efficacy and cost effectivity. Therefore, the discovery of and subsequent analysis of correlates of protection (COP) is essential to monitor the therapy efficacy in patients at much earlier time-points. We have a broad experience in many assays which can help you find a marker which can serve as COP. One might think of the induction of antigen-specific poly-functional T cells (Antigen-specific T cell analyses) or the induction of antibodies of a certain isotype (Antigen-specific B cell analyses).

Contact us for more information or browse through our assays

Also see:

Last edited on: 29 October 2015